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ABSTRACT
Objectives: Diarrhoea and pneumonia remain leading
causes of morbidity and mortality in children under
5 years of age. Little data is available to quantify the
burden of comorbidity and the relationship between
comorbid diarrhoea and pneumonia infections and
mortality. We sought to quantify the relationship
between comorbidity and risk of mortality among
young children in two community-based studies
conducted among South Asian children.
Design: Secondary data analysis of two cohort
studies.
Participants: We identified two cohort studies of
children under 3 years of age with prospective
morbidity at least once every 2 weeks and ongoing
mortality surveillance.
Outcome measures: We calculated the mortality risk
for diarrhoea and acute lower respiratory infection
(ALRI) episodes and further quantified the risk of
mortality when both diseases occur at the same time
using a semiparametric additive model.
Results: Among Nepali children, the estimated
additional risk of mortality for comorbid diarrhoea and
ALRI was 0.0014 (−0.0033, 0.0060). Among South
Indian children, the estimated additional risk of
mortality for comorbid diarrhoea and ALRI was 0.0032
(−0.0098, 0.0162). This risk is in addition to the
single infection risk of mortality observed among these
children.
Conclusions: We observed an additional risk of
mortality in children who experienced simultaneous
diarrhoea and ALRI episodes though the CI was wide
indicating low statistical support. Additional studies
with adequate power to detect the increased risk of
comorbidity on mortality are needed to improve
confidence around the effect size estimate.
BACKGROUND
Diarrhoea and pneumonia remain leading
causes of morbidity and mortality in children
under 5 years of age.1 Young children experi-
ence on average 2.9 episodes of diarrhoea
per year with the highest rates among those
between 6 and 18 months of age.2 Children
under 2 years of age experience multiple
respiratory track infections per year and each
year one in five will have a case of confirmed
pneumonia.1 There is little data available to
quantify the burden of comorbidity (ie, sim-
ultaneous infections)3–5 and even less data
available to describe the relationship
between comorbid infections as a risk factor
for death. Thus far, there has been only one
analysis of a community-based study to assess
the risk of comorbidity on subsequent mor-
tality.3 Although no significant association
was found between comorbidity and risk of
mortality in this study, an increased preva-
lence of comorbidity was observed with
increased disease severity. We sought to
further investigate the relationship between
comorbidity and risk of mortality among
ARTICLE SUMMARY
Article focus
▪ Diarrhoea and pneumonia are leading causes of
morbidity and mortality.
▪ Diarrhoea has been shown to be a risk factor for
pneumonia.
▪ However, little is known about the role of
comorbidity (ie, simultaneous infections) on risk
of mortality.
Key messages
▪ We used data from two previously published
cohort studies with routine morbidity surveil-
lance and ongoing mortality monitoring to quan-
tify the risk of mortality for a single illness and
the added risk if coinfection occurred.
▪ There was no statistically significant additional
risk of mortality for children with coinfections
above and beyond the mortality risk of individual
infection.
Strengths and limitations of this study
▪ Included data from two large studies conducted
among South Asian children to answer this
important question.
▪ Despite analytic rigour, sample sizes were too
small to detect a statistically significant risk
beyond the mortality risk of individual infection.
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young children in two additional community-based
studies conducted among South Asia children.
METHODS
Selection of data sets
We conducted a literature review to identify community-
based studies that included prospective morbidity and
mortality surveillance of children under 5 years of age in
low-income or middle-income countries. We searched
PubMed, Scopus and Google Scholar for studies pub-
lished between 1980 and 2010. The following key words
were used in the search: diarrh(o)ea, pneumonia, acute
lower respiratory infection (ALRI), morbidity and mor-
tality. Inclusion and exclusion criteria were established a
priori. We sought studies with at least 12 months of mor-
bidity and mortality surveillance. We included only those
studies that had household morbidity surveillance at
least once every 2 weeks to record daily diarrhoea and
respiratory tract symptoms in the two previous weeks (or
less) and those that included prospective mortality moni-
toring and used a standard verbal autopsy to determine
cause of death.6 We also conducted an active search of
past large community-based studies within the Child
Health Epidemiology Reference Group (CHERG)
network of investigators. Emails were sent to all possible
investigators identified by CHERG members as those
who might have a qualifying study.
Methods of selected studies
With this two-part process, we identified two studies that
met all inclusion criteria. Both studies enrolled children
under 3 years of age in South Asia. The detailed
methods of both studies have been previously pub-
lished.7 8 In the Nepal Nutrition Intervention Project—
Sarlahi 4 (NNIPS-4), children 1–35 months of age living
in the study areas were enrolled in a micronutrient sup-
plementation trial and received daily zinc, iron, zinc and
iron or placebo. Active morbidity surveillance was con-
ducted twice a week in a subgroup of enrolled children
who were followed for 1 year. In South India, investiga-
tors of the Vitamin A Supplementation in Newborns
Study (VASIN) randomised infants at birth and followed
them every 2 weeks, collecting daily accounts of infant
morbidities, up to 6 months of age. In both studies,
infant and child deaths were assessed using a standard
verbal autopsy.
Study arm inclusion and case definitions
We included the iron and placebo arms from the
NNIPS-4 study. Children receiving zinc were excluded
because the zinc supplementation had a direct impact
on mortality.7 From VASIN, we included both vitamin A
and placebo arms of the study. While vitamin A supple-
mented children did have lower mortality rates, supple-
mentation is now routine in parts of the world with
vitamin A deficiency; thus, combining the two groups
likely represents a more typical child population with
variable vitamin A status and supplementation coverage.
We used prospective morbidity data to quantify the
rates of diarrhoea and ALRI. Case definitions for diar-
rhoea and ALRI episodes were determined by the ori-
ginal studies (table 1). The definitions were identical for
diarrhoea and varied slightly based on collected signs
and symptoms for ALRI. In cases in which morbidity
data were missing in the 2 weeks prior to death, we used
data available from the retrospective questionnaire as
part of the detailed verbal autopsies conducted on all
child deaths. Questions from the retrospective data most
resembling those asked in the morbidity data collection
were used to supplement the prospective data. For both
studies, it was assumed that deaths because of diarrhoea
(definition in table 1) also included a diarrhoea episode
in the 2 weeks prior to death. For VASIN, deaths because
of fever, difficulty breathing and persistent cough in the
verbal autopsy (VA) retrospective questionnaire were
classified with ALRI morbidity in the 2 weeks prior to
death. For NNIPS-4, deaths that indicated difficulty
breathing and fever prior to death were classified with
ALRI morbidity in the 2 weeks prior to death.
STATISTICAL METHODS
We sought to calculate the mortality risk for diarrhoea and
ALRI episodes and further quantify the risk of mortality
when both diseases occur at the same time. We used a
semiparametric additive model to compare the mortality
risk by episode type in the previous week while allowing
estimated risk for those with no ALRI or diarrhoea to vary
by age (our chosen time scale).9 10 This regression model,
defined by Aalen, allows for flexibility in the overall mor-
tality rate, which is modelled non-parametrically for a
given time scale, while the difference between mortality
rates is assumed to be linear. Where model assumptions
hold, the difference in mortality risk depending on
Table 1 Case definitions for diarrhoea and ALRI used to define an episode of diarrhoea and/or ALRI
NNIPS-4 VASIN
Diarrhoea 4 or more loose/watery stools per day with episodes
separated by at least 3 symptom free days
4 or more loose/watery stools per day with episodes
separated by at least 3 symptom free days
ALRI Fever, cough or difficulty breathing with all 3
symptoms on at least 1 day during the episode with
7 or more days between episodes
Cough and difficulty breathing with fever on at least
1 day during the episode with episodes separated by at
least 3 symptom free days
ALRI,acute lower respiratory infection; NNIPS-4, Nepal Nutrition Intervention Project—Sarlahi-4; VASIN, Vitamin A Supplementation in
Newborns Study.
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episode is quantified by a sum of group risks. We con-
ducted the analysis first stratified by treatment groups
within each study (ie, iron vs placebo for NNIPS-4 and
vitamin A vs placebo for VASIN) and combined where no
difference in the effect of comorbidity on mortality risk
was observed between groups. All analyses were conducted
with the open source software R 2.15.011 using the survival
analysis package timereg.12
RESULTS
Selected studies
There were 2610 children enrolled in the NNIPS-4 mor-
bidity substudy with a total of 1730 child-years of observa-
tion and 19 deaths (table 2). In VASIN, there were 11 407
enrolled children who contributed to the active morbid-
ity surveillance in the postnatal period (ie, from 28 days
of age). Among these, there were 3720 child years of
observation and 151 postneonatal deaths (table 2).
MODEL RESULTS
The results of the Aalen regression framework for both
NNIPS-4 and VASIN are presented in table 3. We
present the estimates for regression parameters and
their approximate SE and CIs. These parameters are
interpretable as the additional population mortality rate
in 1 week, or the average additional risk of mortality
within 1 week. The comorbidity parameter is for an
interaction between indicators for ALRI and diarrhoea
in the previous week. These risks are in addition to the
base mortality rate, which is determined by age on a
weekly basis for the duration of the study period (ie, for
12 calendar months of enrollment for NNIPS-4 and
from 28 to 180 days for VASIN). Among Nepali children
(NNIPS-4), the estimated additional risk of mortality for
comorbid diarrhoea and ALRI was 0.0014 (−0.0033,
0.0060). For VASIN, we conducted all analyses stratified
by supplement group and observed no interaction
between intervention group and comorbidity risk and
thus are presenting only the combined results here.
Among South Indian children (VASIN), the estimated
additional risk of mortality for comorbid diarrhoea and
ALRI was 0.0032 (−0.0098, 0.0162).
The estimated risk of mortality from the Aalen regres-
sion model is shown for NNIPS-4 and VASIN in figures 1
and 2. We present the non-parametrically estimated mor-
tality for those children with no ALRI or diarrhoea
episode in the prior week. The estimated risk of mortal-
ity for those with an episode of ALRI alone, with diar-
rhoea alone and with both ALRI and diarrhoea in the
prior week is determined by the sum of this non-
parametric risk and the survival regression parameters
for each group as shown in table 3.
DISCUSSION
We present the risk of mortality due to diarrhoea and
ALRI episodes individually, and the additive risk as a
result of a child having both diarrhoea and respiratory
infections simultaneously. For these analyses, we com-
bined the micronutrient intervention groups after first
assessing each independently and observing no inter-
action. By combining the results, the data are more rep-
resentative of an average low-income and middle-income
population of young children with a wide range of nutri-
tional states. The Cox proportional hazards model is
often used for analysing cohort mortality data like what
we included here from the NNIPS-4 and VASIN studies;
however, the Cox model assumes that the ratio of mor-
tality rates is constant over time. This can be a difficult
assumption when examining the interaction of effects as
in our case with comorbidity. The Cox model is also dif-
ficult to interpret, because mortality risk due to multiple
effects is often assumed additive and Cox parameters
are multiplicative. Cohort mortality data has also been
analysed with generalised estimating equations (GEE).3
GEE is an improvement with regard to the flexibility for
non-proportional mortality rates, but is sensitive to
missing outcomes, which is a potential issue for cohort
survival data.13 We chose to use an additive model9 10
that allows for more flexibility in comparing mortality
rates over time, especially for covariates that vary within
individuals,14 as in our case for recent ALRI and diar-
rhoea symptoms as risk factors for mortality. Our
primary interest is also to specify the risk of mortality for
children with comorbid symptoms as a sum of the risk
due to ALRI and that due to diarrhoea. This analysis
Table 2 Mortality in the NNIPS-4 morbidity substudy and the VASIN study by intervention arm
Study arm
Number of children
observed
Observation time
(years) Deaths
Mortality rate
(per year)
ALRI
deaths*
Diarrhoea
deaths*
NNIPS-4
Iron 576 366.2 4 0.0109 0 0
Placebo 2034 1363.8 15 0.0110 2 5
VASIN
Placebo 5713 1860.3 84 0.0452 19 18
Vitamin A 5694 1859.9 67 0.0360 22 11
*Assigned primary cause of death by verbal autopsy.
ALRI,acute lower respiratory infection; NNIPS-4, Nepal Nutrition Intervention Project—Sarlahi-4; VASIN, Vitamin A Supplementation in
Newborns Study.
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allows us to test whether mortality risk is truly additive
over time, and if so, to compare the sum of risks and to
make inference on the difference between sums of risks.
We did observe an additional risk of mortality among
children who experienced simultaneous diarrhoea and
ALRI episodes in both the NNIPS-4 and VASIN data sets,
but both estimates had wide CIs and thus we lacked stat-
istical power. There are several possible features in the
data that may have contributed to these results. First, the
actual synergism between ALRI and diarrhoea may be
very close to zero (or less than zero), and the predicted
positive synergism a randomly observed phenomena. It
is also possible that lack of data, particularly low
observed mortality rates on average for each cohort,
together with the small number of individuals with
comorbidity symptom classification, may have made a
meaningful comorbid effect difficult to detect. The low
mortality rates may be the result of a study Hawthorne
effect. In both studies, morbidity surveillance was
routine; sometimes involvement in a study and the
awareness that someone is coming to ask questions
about the health of the child can increase care-seeking
behaviour such that children enrolled in the study
would be more likely to receive timely care than those
who were not in the study. Prompt and appropriate care
seeking for diarrhoea and pneumonia will decrease dis-
eases severity and overall mortality from these two dis-
eases. The total number of deaths in the NNIPS-4 study
was particularly low, but even with 151 postnatal deaths
in VASIN, only three of these deaths were associated
with comorbidity between ALRI and diarrhoea
symptoms.
At the start of our search for data sets fitting our tight
inclusion and exclusion criteria, we were hopeful that
rigorous searching would uncover more than two
studies. Although there are many large-scale studies
Table 3 Additive model of mortality risk for Nepali (NNIPS-4) and South Indian (VASIN) children, Aalen additive hazards
model with robust SEs, combining treatment groups
95% CI
Estimate SE Z P Lower Upper
Nepal
Diarrhoea, but no ALRI 0.0002 0.0002 1.07 0.287 −0.0002 0.0006
ALRI, but no diarrhoea 0.0007 0.0005 1.33 0.185 −0.0003 0.0016
Additional risk associated with having both conditions
simultaneously
0.0014 0.0024 0.573 0.567 −0.0033 0.0060
South India
Diarrhoea, but no ALRI 0.0045 0.0008 5.55 <0.001 0.0029 0.0061
ALRI, but no diarrhoea 0.0034 0.0011 2.98 0.003 0.0012 0.0056
Additional risk associated with having both conditions
simultaneously
0.0032 0.0066 0.49 0.628 −0.0098 0.0162
Figure 1 Mortality rates estimated by the linear survival
regression model in the Nepal data set, conditional on
episode type in the previous week and age in weeks.
Figure 2 Mortality rates estimated by the linear survival
regression model in the South India data set, conditional on
episode type in the previous week and age in weeks.
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monitoring mortality among young children and many
other studies with active morbidity surveillance, combin-
ing these two attributes limited the studies available for
inclusion. Because of the demands of routine household
visits, sample sizes are rarely large enough to include
mortality and all such studies would require community
involvement and large budgets. Given the intense nature
of conducting a study with active morbidity surveillance
and the large sample size needed to complete a study
with verbal autopsies, it is unlikely that we missed eli-
gible studies through our intense search process.
There are several pathways that may explain the added
risk of mortality observed among children with simultan-
eous diarrhoea and ALRI infections. Several studies have
reported diarrhoea as a risk factor for ALRI15–17; these
children may have begun with an episode of diarrhoea
which leads to nutritional setbacks, compromising the
immune system, and thus leaving the child susceptible
to subsequent infection18 and the development of more
severe infections increasing the risk for mortality.19 It is
also possible that respiratory infection or the immune
response to it may alter the gut flora increasing suscepti-
bility to or severity of intestinal infections.20 It is difficult
in community-based studies to determine the exact
timing of infection and illness because presentation with
signs or symptoms may be several days after initial infec-
tion. Furthermore, in communities in developing coun-
tries, children have high rates of infection due to poor
environmental conditions and even simultaneous infec-
tious illnesses occurring by chance could result in addi-
tive or greater risk of death. Several studies have
reported an increased risk of mortality among children
hospitalised with multiple infections (including respira-
tory signs and symptoms)21 and the presence of multiple
conditions reported among children who died in hos-
pital settings despite cause of death being assigned to
one disease.22 Although the concept of comorbidity as
an increased risk may be noted in the literature and
acknowledged clinically among pediatricians, we lack the
evidence to accurately quantify the value of this added
risk and most importantly to then understand what
interventions could be put in place to prevent dual
severe infections leading to mortality.
Further study could shed light on these issues and the
underlying relationships between child mortality, ALRI and
diarrhoea. Several issues would need to be considered to
plan a study for detecting differences in mortality rates for
comorbidity compared to the additive risk of ALRI and diar-
rhoea alone. Of primary concern is the study size. To esti-
mate the size of a study that would be needed to observe a
statistically significant effect, we conducted a power analysis
assuming that the ratio of comorbidity to single disease epi-
sodes observed in the South Indian data would be observed
in future studies, that is, that for every 100 children with
ALRI or diarrhoea symptoms alone, 4 children would have
both ALRI and diarrhoea symptoms simultaneously. We also
assumed that among children ever reporting comorbidity,
the weekly point prevalence of comorbid symptoms would
be again consistent with the VASIN data (ie, 23%) and that
overall mortality rates would be similar to those in the
VASIN data. Given these assumptions, and similar incidence
rates to those in the VASIN data, a study enrolling children
at 1 month and following them until 6 months of age would
need to enroll 35 900 infants to have 80% power to find a
significant comorbid effect on the mortality rate with a type
1 error rate of 5%.23 With similar incidence rates to those
observed in VASIN, a study of this size would produce 8720
children with ALRI or diarrhoea symptoms during the study
period, a critical number determining power in a study of
the comorbidity effect on mortality.
A study of this magnitude is not likely in the near future
and may be even harder to envision as under five mortality
rates decline in many parts of the world. Despite this, diar-
rhoea and pneumonia remaining the leading causes of
death among children under 5 years of age in low-income
and middle-income countries1 and the possibility that joint
infection could increase the risk for mortality is important
to recognise. This knowledge highlights the importance of
prevention of both diseases with improved water and sanita-
tion and nutrition, and appropriate case management.
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